Opko Health Aktie
WKN DE: A0MUUJ / ISIN: US68375N1037
|
16.11.2026 08:23:50
|
Cocrystal Pharma Posts Wider Q3 Loss, Led By Norovirus Challenge Study Costs
(RTTNews) - Cocrystal Pharma, Inc. (COCP), a clinical stage biotechnology firm, on Sunday reported a wider loss in its third quarter, driven by higher clinical trial and related expenses mainly associated with the Phase 1b norovirus challenge study of norovirus candidate CDI-988.
Loss for the third quarter was $3.444 million, or $0.20 per share, compared to a loss of $2.049 million, or $0.19 per share last year.
Loss from operations was $3.489 million, as against the year-ago loss of $2.089 million.
Total operating expenses rose to $3.594 million from $2.089 million of the previous year.
Research and development expenses amounted to $1.978 million, up from the prior year quarter's $0.954 million. The year-over-year increase was mainly related to the Phase 1b norovirus challenge study of the norovirus candidate CDI-988 in 2026, the preliminary efficacy results of which are expected by the end of 2026.
The company's revenue and grant income totaled $0.105 million, representing payments from the NIH SBIR award for an influenza A/B inhibitor program, while no revenue was recorded in the prior year.
Cocrystal reported unrestricted cash as of September 30, of $4.873 million, reflecting $5.0 million in gross proceeds from the private placement with its longtime investor OPKO Health, Inc. (OPK).
COCP shares closed Friday on the Nasdaq at $0.9801, down 1 percent.
For more earnings news, earnings calendars, and earning of stocks, visit rttnews.com
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Opko Health IncShs
| Keine Nachrichten verfügbar. |
Analysen zu Opko Health IncShs
Aktien in diesem Artikel
| Opko Health IncShs | 1,46 | -5,19% |
|